COVID‐19: Consider IL‐6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, Garima Sharma, Sang‐Soo Lee, Govindasamy Agoramoorthy
Abstract
COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL-6R) antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL-6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL-6R antagonists for the therapy of cytokine storm syndrome severe acute respiratory syndrome coronavirus 2 infected persons to enhance the therapeutic options for cytokine storm.
Topics & Concepts
Cytokine stormTocilizumabCytokine release syndromeMedicineCytokineReceptor antagonistImmunologyCoronavirus disease 2019 (COVID-19)Interleukin 1 receptor antagonistVirologyInterleukin 6AntagonistReceptorInternal medicineInfectious disease (medical specialty)DiseaseRheumatoid arthritisCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research